IPTACOPAN ASH UPDATE
12 g/dL
Iptacopan monotherapy was superior to SoC at increasing Hb level
from baseline
Mean Hb (SD) over time during the 24-week randomized treatment period³
Mean Hb level, g/dL (SD)
15-
14-
13-
12
11
10
+
0
8
BL Wk1 Wk2
Wk4
Wk6
Wk8
Wk12
Wk16
Wk18
Wk20
Wk22
Wk24
Patients with available data
Iptacopan
62 61 59
60
Anti-C5 SoC 35 29
27
32
59
32
59
31
Study visit
60
33
59
59
59
57
28
34
32
32
61
34
7
NOVARTIS | Reimagining Medicine
Adjusted mean Hb change from baseline¹ (95% CI) was +3.59 (3.32, 3.86) g/dL for iptacopan vs -0.04 (−0.42, 0.35) g/dL for SoC, with a difference of +3.63 (3.18, 4.08) g/dL (P<0.00012).
1. Between Days 126 and 168 (excluding values within 30 days of RBC transfusion). 2. A repeated measures model, adjusting for covariates including baseline Hb, was used for comparisons between the treatment arms. P value is two-sided
and unadjusted. 3. Includes post-transfusion data. 2/62 patients in the iptacopan arm and 21/35 patients in the SoC arm had RBC transfusions between Days 14 and 168. BL = baseline Wk = week
13
IPTACOPAN ASH UPDATE | DECEMBER 13, 2022View entire presentation